Sinopharm (HKG:1099) attributable profit fell to 7.05 billion yuan in 2024 from 9.05 billion yuan in 2023, according to a Monday filing with the Hong Kong bourse.
Earnings per share at the pharmaceutical company decreased to 2.26 yuan from 2.90 yuan a year earlier. Analysts at Visible Alpha estimated EPS at 2.67 yuan.
Revenue declined to 584.5 billion yuan from 596.6 billion yuan in the previous year. Visible Alpha analysts forecast revenue at 600.1 billion yuan.
The company declared a final dividend of 0.68 yuan per share, payable Aug. 12 to shareholders on record as of June 23.
Shares slipped 4% during Monday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.